Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 296 articles:
HTML format



Single Articles


    July 2024
  1. MOTA SM, Priester A, Shubert J, Bong J, et al
    Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.
    J Urol. 2024;212:52-62.
    PubMed     Abstract available


  2. MIAN BM, Bernstein A, Kaufman RP Jr, Fisher HAG, et al
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:227-228.
    PubMed    


  3. NAHAS WC, Rodrigues GJ, Rodrigues Goncalves FA, Sawczyn GV, et al
    Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:32-40.
    PubMed     Abstract available


  4. TILL C, Goodman PJ, Tangen C, Lucia MS, et al
    Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial.
    J Urol. 2024;212:228-229.
    PubMed    


    June 2024
  5. LEWICKI P, Morgan T
    The Genomics and Natural History of MRI Visible vs. Invisible Prostate Cancer: Clinical Implications".
    J Urol. 2024 Jun 12:101097JU0000000000004104. doi: 10.1097/JU.0000000000004104.
    PubMed    


  6. MOSES RA, Hunter AE, Brandes ER, Zhang Z, et al
    Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
    J Urol. 2024;211:765-774.
    PubMed     Abstract available


  7. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:802-803.
    PubMed    


    May 2024
  8. BAHLER CD, Tachibana I, Tann M, Collins K, et al
    Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 May 24:101097JU0000000000004032. doi: 10.1097/JU.0000000000004032.
    PubMed     Abstract available


  9. HUSSAIN J, Sanchez-Salas R
    Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
    PubMed    


  10. EMMETT L, Papa N, Hope TA, Fendler W, et al
    Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
    J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010.
    PubMed     Abstract available


  11. TRINH QD, Labban M, Daniels D, Feldman A, et al
    Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color.
    J Urol. 2024 May 4:101097JU0000000000003931. doi: 10.1097/JU.0000000000003931.
    PubMed    


  12. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    PubMed     Abstract available


  13. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    PubMed     Abstract available


  14. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    PubMed    


  15. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    PubMed    


    April 2024
  16. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    PubMed     Abstract available


  17. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    PubMed     Abstract available


  18. URABE F, Yoshioka T, Tashiro K, Kimura T, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:622.
    PubMed    


  19. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:623-624.
    PubMed    


  20. CAKICI MC, Ozgur Kazan H, Yildirim A
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:624-625.
    PubMed    


    March 2024
  21. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
    Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
    J Urol. 2024;211:376-383.
    PubMed     Abstract available


  22. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
    Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    J Urol. 2024;211:400-406.
    PubMed     Abstract available


  23. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
    Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
    J Urol. 2024;211:384-391.
    PubMed     Abstract available


  24. HOUGEN HY, Sjoberg DD, Thomas J, Mahal BA, et al
    Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
    J Urol. 2024;211:392-399.
    PubMed     Abstract available


    February 2024
  25. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
    PubMed     Abstract available


  26. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
    PubMed     Abstract available


  27. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
    PubMed     Abstract available


  28. ESCOBAR AJ, Krishna S, Flowers KM, Abello A, et al
    Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial.
    J Urol. 2024;211:214-222.
    PubMed     Abstract available


  29. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:205-213.
    PubMed     Abstract available


  30. MISTRY NA, Sun Z, Sweis J, McCall C, et al
    Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
    J Urol. 2024;211:223-233.
    PubMed     Abstract available


  31. BECHTEL MD, Michel C, Srinivasan P, Chalise P, et al
    Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.
    J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
    PubMed     Abstract available


  32. BERNARDINO R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, et al
    Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients.
    J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
    PubMed     Abstract available


    January 2024
  33. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024 Jan 15:101097JU0000000000003835. doi: 10.1097/JU.0000000000003835.
    PubMed    


  34. GARNICK MB, Hafron J, Crawford ED
    Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2024 Jan 5:101097JU0000000000003831. doi: 10.1097/JU.0000000000003831.
    PubMed    


    December 2023
  35. VAN NESTE L, Henao R, Wojno KJ, Signes J, et al
    Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
    J Urol. 2023 Dec 26:101097JU0000000000003824. doi: 10.1097/JU.0000000000003824.
    PubMed     Abstract available


  36. STIRA J, Gravina C, Lombardo R, De Nunzio C, et al
    Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone?Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Dec 22:101097JU0000000000003830. doi: 10.1097/JU.0000000000003830.
    PubMed    


  37. REZAEE ME, Pallauf M, Fletcher SA, Han M, et al
    Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy.
    J Urol. 2023 Dec 18:101097JU0000000000003825. doi: 10.1097/JU.0000000000003825.
    PubMed     Abstract available


    November 2023
  38. TOSOIAN JJ, Yu A, Brisbane WG
    Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time.
    J Urol. 2023 Nov 27:101097JU0000000000003797. doi: 10.1097/JU.0000000000003797.
    PubMed    


  39. JOYCE DD, Filson CP, Herrel LA
    What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2023 Nov 27:101097JU0000000000003798. doi: 10.1097/JU.0000000000003798.
    PubMed    


  40. PAGADALA MS, Ryan S, Carter H, Javier-DesLoges J, et al
    Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort.
    J Urol. 2023 Nov 27:101097JU0000000000003794. doi: 10.1097/JU.0000000000003794.
    PubMed    


  41. LEPOR H
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
    J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
    PubMed    


  42. CHEN Y, Liang Z, Yan W
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
    J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
    PubMed    


  43. SESSINE MS, Radoiu CS, Qi J, Labardee C, et al
    Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
    J Urol. 2023 Nov 6:101097JU0000000000003775. doi: 10.1097/JU.0000000000003775.
    PubMed     Abstract available


    October 2023
  44. CRAWFORD ED, Hafron JM, Debruyne F, Wallis C, et al
    Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Oct 5:101097JU0000000000003721. doi: 10.1097/JU.0000000000003721.
    PubMed     Abstract available


  45. TERAMOTO Y, Wang Y, Miyamoto H
    Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?
    J Urol. 2023;210:639-648.
    PubMed     Abstract available


    September 2023
  46. MONTORSI F, Gandaglia G, Salonia A, Briganti A, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003683. doi: 10.1097/JU.0000000000003683.
    PubMed    


  47. SHAH N, Ioffe V
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003682. doi: 10.1097/JU.0000000000003682.
    PubMed    


    August 2023
  48. TANG W, Tang Y, Qi L, Zhang Y, et al
    BPH-related False Positive of PSMA-PET in the Diagnosis of Prostate Cancer: the Achilles' Heel of Biopsy-free Radical Prostatectomy?
    J Urol. 2023 Aug 30:101097JU0000000000003680. doi: 10.1097/JU.0000000000003680.
    PubMed     Abstract available


  49. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Aug 25:101097JU0000000000003675. doi: 10.1097/JU.0000000000003675.
    PubMed    


  50. JOYCE DD, Schulte PJ, Kwon ED, Dusetzina SB, et al
    Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.
    J Urol. 2023;210:290-298.
    PubMed     Abstract available


  51. URKMEZ A, Davis JW
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Reply.
    J Urol. 2023;210:249.
    PubMed    


  52. OZDEN E, Ozturk E, Turgut AT
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Letter.
    J Urol. 2023;210:248-249.
    PubMed    


  53. BERMAN DM, Lee AY, Lesurf R, Patel PG, et al
    Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.
    J Urol. 2023;210:257-271.
    PubMed     Abstract available


  54. CHANG K, Greenberg SA, Cowan JE, Parker R, et al
    Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging.
    J Urol. 2023;210:281-289.
    PubMed     Abstract available


  55. BRITTON CJ, Sharma V, Fadel AE, Bearrick E, et al
    Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes.
    J Urol. 2023;210:312-322.
    PubMed     Abstract available


    July 2023
  56. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jul 28:101097JU0000000000003633. doi: 10.1097/JU.0000000000003633.
    PubMed    


  57. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Jul 14:101097JU0000000000003614. doi: 10.1097/JU.0000000000003614.
    PubMed    



  58. MP44-04 Importance of the Ultrasound Characteristics of Regions of Interest by MRI and the Additional Target Biopsy Around Their Peri-hypoechoic Lesions in MR/TRUS Software Fusion Biopsy to Improve Detection Rate of Prostate Cancer.
    J Urol. 2023;210:223.
    PubMed    


    June 2023
  59. YIM K, Ma C, Carlsson S, Lilja H, et al
    Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.
    J Urol. 2023 Jun 29:101097JU0000000000003603. doi: 10.1097/JU.0000000000003603.
    PubMed     Abstract available


  60. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
    J Urol. 2023 Jun 23:101097JU0000000000003598. doi: 10.1097/JU.0000000000003598.
    PubMed    


  61. MAI Z, Zhou Z
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Letter.
    J Urol. 2023 Jun 22:101097JU0000000000003597. doi: 10.1097/JU.0000000000003597.
    PubMed    


  62. JOYCE DD, Qin X, Sharma V, Boorjian SA, et al
    The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.
    J Urol. 2023 Jun 21:101097JU0000000000003592. doi: 10.1097/JU.0000000000003592.
    PubMed     Abstract available


  63. YANAGISAWA T, Rajwa P, Kawada T, Mori K, et al
    Efficacy of Systemic Treatment in Prostate Cancer Patients with Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    J Urol. 2023 Jun 20:101097JU0000000000003594. doi: 10.1097/JU.0000000000003594.
    PubMed     Abstract available


  64. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jun 19:101097JU0000000000003587. doi: 10.1097/JU.0000000000003587.
    PubMed    


  65. WYSOCK JS, Rapoport E, Hernandez H, Gogaj R, et al
    Biopsy Assessment of Oncologic Control Three Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men with Intermediate Risk Prostate Cancer.
    J Urol. 2023 Jun 7:101097JU0000000000003569. doi: 10.1097/JU.0000000000003569.
    PubMed     Abstract available


  66. BRAILLON A
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Jun 1:101097JU0000000000003567. doi: 10.1097/JU.0000000000003567.
    PubMed    


    May 2023
  67. SHAH N, Ioffe V
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Letter.
    J Urol. 2023 May 30:101097JU0000000000003564. doi: 10.1097/JU.0000000000003564.
    PubMed    


  68. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 18:101097JU0000000000003541. doi: 10.1097/JU.0000000000003541.
    PubMed    


  69. ANDREWS JR, Sood A, Chapin BF
    Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.
    J Urol. 2023 May 17:101097JU0000000000003495. doi: 10.1097/JU.0000000000003495.
    PubMed    


  70. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 3:101097JU0000000000003477. doi: 10.1097/JU.0000000000003477.
    PubMed    



  71. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol. 2023 May 2:101097JU0000000000003518. doi: 10.1097/JU.0000000000003518.
    PubMed     Abstract available


  72. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023;209:1026-1028.
    PubMed    


  73. AVOLIO PP, Polascik TJ, Rastinehad A, de la Rosette J, et al
    Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. Letter.
    J Urol. 2023;209:848-849.
    PubMed    


  74. SHAH RB
    Point/Counterpoint: Gleason Score 6/Grade Group 1 Prostate Cancer Should Renamed as "Non-cancer" to Improve Public Health-A Wrong Idea From a Pathologist's Perspective.
    J Urol. 2023 May 1:101097JU0000000000003510. doi: 10.1097/JU.0000000000003510.
    PubMed    


  75. ZHOU M, Paner GP
    Grade Group 1 (Gleason Score 6) Prostate Cancer Should be Re-named to Improve Public Health: Pathologists' Perspective.
    J Urol. 2023 May 1:101097JU0000000000003511. doi: 10.1097/JU.0000000000003511.
    PubMed    


    April 2023
  76. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 PET in Men with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
    J Urol. 2023 Apr 26:101097JU0000000000003493. doi: 10.1097/JU.0000000000003493.
    PubMed     Abstract available


  77. LOWRANCE W, Dreicer R, Jarrard DF, Scarpato KR, et al
    Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).
    J Urol. 2023 Apr 25:101097JU0000000000003452. doi: 10.1097/JU.0000000000003452.
    PubMed     Abstract available


  78. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.
    J Urol. 2023 Apr 25:101097JU0000000000003491. doi: 10.1097/JU.0000000000003491.
    PubMed     Abstract available


  79. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.
    J Urol. 2023 Apr 25:101097JU0000000000003492. doi: 10.1097/JU.0000000000003492.
    PubMed     Abstract available


  80. MARTINI A, Wever L, Soeterik TFW, Rakauskas A, et al
    Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
    J Urol. 2023 Apr 13:101097JU0000000000003442. doi: 10.1097/JU.0000000000003442.
    PubMed     Abstract available


  81. BARABAN E, Erak E, Fatima A, Akbari A, et al
    Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
    J Urol. 2023 Apr 12:101097JU0000000000003461. doi: 10.1097/JU.0000000000003461.
    PubMed     Abstract available


  82. HO MD, Ross AE, Eggener SE
    Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance.
    J Urol. 2023 Apr 12:101097JU0000000000003454. doi: 10.1097/JU.0000000000003454.
    PubMed     Abstract available


  83. SHAH N, Ioffe V
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 11:101097JU0000000000003458. doi: 10.1097/JU.0000000000003458.
    PubMed    


  84. KA-FUNG CHIU P, Leow JJ, Chiang CH, Mok A, et al
    Prostate Health Index Density Outperforms PSA Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal MRI Prostates: A Multicenter Evaluation.
    J Urol. 2023 Apr 10:101097JU0000000000003450. doi: 10.1097/JU.0000000000003450.
    PubMed     Abstract available


  85. GUIDOTTI A, Lombardo R, De Nunzio C
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003456. doi: 10.1097/JU.0000000000003456.
    PubMed    


  86. HABASHY D, Reddy D, Peters M, Shah TT, et al
    Evaluation of Outcomes following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    J Urol. 2023 Apr 4:101097JU0000000000003443. doi: 10.1097/JU.0000000000003443.
    PubMed     Abstract available



  87. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2023;209:815.
    PubMed    


    March 2023
  88. BREEN KE, Symecko H, Spielman K, Gebert R, et al
    Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
    J Urol. 2023 Mar 28:101097JU0000000000003186. doi: 10.1097/JU.0000000000003186.
    PubMed     Abstract available


  89. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Mar 23:101097JU0000000000003421. doi: 10.1097/JU.0000000000003421.
    PubMed    


  90. JIN S, Wu L, Mai Z, Yan W, et al
    A Multicenter, Randomized, Single-Blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-Intermediate Risk Prostate Cancer. Letter.
    J Urol. 2023 Mar 16:101097JU0000000000003404. doi: 10.1097/JU.0000000000003404.
    PubMed    


  91. ZHANG K, Teoh J, Laguna P, Ng CF, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.
    J Urol. 2023 Mar 16:101097JU0000000000003405. doi: 10.1097/JU.0000000000003405.
    PubMed    


  92. SCHNEIDER AC, Chandrasekar T, Bowler N, Fogg R, et al
    Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
    J Urol. 2023 Mar 9:101097JU0000000000003396. doi: 10.1097/JU.0000000000003396.
    PubMed     Abstract available


  93. HUSSAIN M, Sternberg CN, Efstathiou E, Fizazi K, et al
    Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
    J Urol. 2023;209:532-539.
    PubMed     Abstract available


    February 2023
  94. SWAMI U, Hong A, El-Chaar NN, Ramaswamy K, et al
    The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer.
    J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
    PubMed     Abstract available


  95. LEAPMAN MS, Wang R, Loeb S, Seibert TM, et al
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
    J Urol. 2023 Feb 8:101097JU0000000000003159. doi: 10.1097/JU.0000000000003159.
    PubMed     Abstract available


  96. PATEL N, Hughes A, Zhang H, Brisbane W, et al
    Utility of MRI for Localizing Prostate Cancer near the Urethra in Men Who are Candidates for Focal Gland Ablation.
    J Urol. 2023 Feb 8:101097JU0000000000003197. doi: 10.1097/JU.0000000000003197.
    PubMed     Abstract available



  97. Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
    J Urol. 2023;209:450.
    PubMed    


  98. SCHWEIZER MT, True L, Gulati R, Zhao Y, et al
    Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
    J Urol. 2023;209:354-363.
    PubMed     Abstract available


    January 2023
  99. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2023 Jan 25:101097JU0000000000003180. doi: 10.1097/JU.0000000000003180.
    PubMed    


  100. TOUIJER K, Plata Bello A
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Reply.
    J Urol. 2023 Jan 19:101097JU0000000000003178. doi: 10.1097/JU.0000000000003178.
    PubMed    


  101. DE BARROS HA, Berrens AC, Donswijk ML, Wit EMK, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Letter.
    J Urol. 2023 Jan 17:101097JU0000000000003177. doi: 10.1097/JU.0000000000003177.
    PubMed    


  102. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
    Expression of Concern: G Protein beta3 Subunit Gene C825T Polymorphism and its Association with the Presence and Clinicopathological Characteristics of Prostate Cancer.
    J Urol. 2023 Jan 10:101097JU0000000000003145. doi: 10.1097/JU.0000000000003145.
    PubMed    


  103. CARROLL P
    Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply.
    J Urol. 2023;209:73.
    PubMed    


  104. SHOJI S, Kaya T, Tanaka Y, Uemura K, et al
    Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reportin
    J Urol. 2023;209:187-197.
    PubMed     Abstract available


    December 2022
  105. LIN DW
    Point-Counterpoint: Active Surveillance Should Still be Preferred Management for All (or Nearly All) Men with Low Risk Prostate Cancer.
    J Urol. 2022 Dec 27:101097JU0000000000003134. doi: 10.1097/JU.0000000000003134.
    PubMed    


  106. TIMILSHINA N, Alibhai SMH, Tomlinson G, Sander B, et al
    Long-Term Outcomes following Active Surveillance of Low-Grade Prostate Cancer: A Population-Based Study Using a Landmark Approach.
    J Urol. 2022 Dec 7:101097JU0000000000003097. doi: 10.1097/JU.0000000000003097.
    PubMed     Abstract available


  107. HIGANO CS, Hafron J
    Adherence With Oral Anticancer Therapies: Clinical Trial versus Real-World Experiences with a Focus on Prostate Cancer.
    J Urol. 2022 Dec 6:101097JU0000000000003081. doi: 10.1097/JU.0000000000003081.
    PubMed     Abstract available


  108. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022;208:1349-1351.
    PubMed    


  109. ANDREWS JR, Ahmed ME, Sharma V, Britton C, et al
    Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
    J Urol. 2022;208:1240-1249.
    PubMed     Abstract available


  110. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003088. doi: 10.1097/JU.0000000000003088.
    PubMed    


  111. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003080. doi: 10.1097/JU.0000000000003080.
    PubMed     Abstract available


    November 2022
  112. DE LA ROSETTE J, Dominguez-Escrig J, Zhang K, Teoh J, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
    J Urol. 2022 Nov 28:101097JU0000000000003051. doi: 10.1097/JU.0000000000003051.
    PubMed     Abstract available


  113. PITTMAN A, Moses KA, Washington SL 3rd
    Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer.
    J Urol. 2022 Nov 17:101097JU0000000000003000. doi: 10.1097/JU.0000000000003000.
    PubMed    


  114. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Nov 16:101097JU0000000000003046. doi: 10.1097/JU.0000000000003046.
    PubMed    


  115. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2022 Nov 14:101097JU0000000000003049. doi: 10.1097/JU.0000000000003049.
    PubMed     Abstract available


  116. MARTINI A, Valerio M
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
    J Urol. 2022 Nov 11:101097JU0000000000003055. doi: 10.1097/JU.0000000000003055.
    PubMed    


  117. BOWER PE
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Letter.
    J Urol. 2022 Nov 11:101097JU0000000000003054. doi: 10.1097/JU.0000000000003054.
    PubMed    


  118. LANNES F, Baboudjian M, Ruffion A, Rouy M, et al
    Radioisotope-Guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients with Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
    J Urol. 2022 Nov 4:101097JU0000000000003043. doi: 10.1097/JU.0000000000003043.
    PubMed     Abstract available


  119. OZMAN O, Tillier CN, van Muilekom E, van de Poll-Franse LV, et al
    Financial Toxicity After Robot-Assisted Radical Prostatectomy and Its Relation with Oncologic, Functional Outcomes.
    J Urol. 2022;208:978-986.
    PubMed     Abstract available


  120. DOAN P, Scheltema MJ, Amin A, Shnier R, et al
    Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
    J Urol. 2022;208:1028-1036.
    PubMed     Abstract available


  121. MAZZONE E, Gandaglia G, Stabile A, Bravi CA, et al
    Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
    J Urol. 2022;208:1046-1055.
    PubMed     Abstract available


  122. FILSON CP, Zhu K, Huang Y, Zheng Y, et al
    Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
    J Urol. 2022;208:1037-1045.
    PubMed     Abstract available


    October 2022
  123. PAUDEL R, Madan R, Qi J, Ferrante S, et al
    The Use and Short-term Outcomes of Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer Managed With Active Surveillance: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2022 Oct 13:101097JU0000000000003012. doi: 10.1097/JU.0000000000003012.
    PubMed     Abstract available


  124. HANSEN NF, Linscott JA, Hayn MH, Ryan ST, et al
    PSA testing behaviors for prostate cancer screening among U.S. immigrants: a cross-sectional analysis using the NHIS.
    J Urol. 2022 Oct 11:101097JU0000000000002993. doi: 10.1097/JU.0000000000002993.
    PubMed     Abstract available


  125. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Oct 10:101097JU0000000000003008. doi: 10.1097/JU.0000000000003008.
    PubMed    


  126. BABOUDJIAN M, Ploussard G
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort. Letter.
    J Urol. 2022 Oct 10:101097JU0000000000002991. doi: 10.1097/JU.0000000000002991.
    PubMed    


  127. ZATTONI F, Marra G, Kasivisvanathan V, Grummet J, et al
    The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi
    J Urol. 2022;208:830-837.
    PubMed     Abstract available


  128. RAVI P, Kwak L, Xie W, Kelleher K, et al
    Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
    J Urol. 2022;208:838-845.
    PubMed     Abstract available


  129. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Nonmetastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2022;208:846-854.
    PubMed     Abstract available


    September 2022
  130. LABBATE CV, Klotz L, Morrow M, Cooperberg M, et al
    Focal Therapy for Prostate Cancer -Evolutionary Parallels to Breast Cancer Treatment.
    J Urol. 2022 Sep 21:101097JU0000000000002972. doi: 10.1097/JU.0000000000002972.
    PubMed     Abstract available


  131. ROULEAU M, Neveu B, Caron P, Morin F, et al
    Extensive Alteration of Androgen Precursor Levels after Castration in Prostate Cancer Patients and Their Association with Active Androgen Level.
    J Urol. 2022 Sep 14:101097JU0000000000002923. doi: 10.1097/JU.0000000000002923.
    PubMed     Abstract available


  132. JOYCE DD, Sharma V, Jiang DH, Van Houten HK, et al
    Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
    J Urol. 2022 Sep 12:101097JU0000000000002856. doi: 10.1097/JU.0000000000002856.
    PubMed     Abstract available


  133. LOPEZ BM, Boville GA, Bernardos GB, Marckert XA, et al
    Focal Therapy of Prostate Cancer Index Lesion with Irreversible Electroporation. A Prospective Study with a Median Follow-Up of Three Years.
    J Urol. 2022 Sep 8:101097JU0000000000002970. doi: 10.1097/JU.0000000000002970.
    PubMed     Abstract available


  134. DE LA CALLE CM, Mamawala MM, Landis P, Macura KJ, et al
    Clinical Significance of Perineural Invasion in Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2022 Sep 8:101097JU0000000000002963. doi: 10.1097/JU.0000000000002963.
    PubMed     Abstract available


  135. SHEE K, Washington SL 3rd, Cowan JE, de la Calle CM, et al
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort.
    J Urol. 2022 Sep 6:101097JU0000000000002956. doi: 10.1097/JU.0000000000002956.
    PubMed     Abstract available


  136. SHIRK JD, Reiter R, Wallen EM, Pak R, et al
    Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial.
    J Urol. 2022;208:618-625.
    PubMed     Abstract available


    August 2022
  137. DE B, Pasalic D, Barocas DA, Wallis CJD, et al
    Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study.
    J Urol. 2022 Aug 25:101097JU0000000000002902. doi: 10.1097/JU.0000000000002902.
    PubMed     Abstract available


  138. TROCK BJ, Jing Y, Mabey B, Sangale Z, et al
    Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy.
    J Urol. 2022 Aug 25:101097JU0000000000002922. doi: 10.1097/JU.0000000000002922.
    PubMed    


  139. KIM IE JR, Pareek G
    The Key to Addressing Disparities in Prostate Cancer: Urologists in Advocacy?
    J Urol. 2022 Aug 24:101097JU0000000000002930. doi: 10.1097/JU.0000000000002930.
    PubMed    


  140. RACHUBINSKI P, Witt JH, Budaus L, Zinke J, et al
    Precision-Guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious mpMRI Lesions.
    J Urol. 2022 Aug 24:101097JU0000000000002921. doi: 10.1097/JU.0000000000002921.
    PubMed     Abstract available


  141. GABRIELSON AT, Choi U, Fletcher SA, Pavlovich CP, et al
    Lost in Transparency: The 21st Century Cures Act ("Open Notes") and Prostate Cancer Care.
    J Urol. 2022 Aug 19:101097JU0000000000002924. doi: 10.1097/JU.0000000000002924.
    PubMed    


  142. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Aug 19:101097JU0000000000002909. doi: 10.1097/JU.0000000000002909.
    PubMed    


  143. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Aug 16:101097JU0000000000002870. doi: 10.1097/JU.0000000000002870.
    PubMed    


  144. ABUSAMRA SM, Solorzano MA, Luke M, Quarles J, et al
    Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer.
    J Urol. 2022 Aug 5:101097JU0000000000002865. doi: 10.1097/JU.0000000000002865.
    PubMed     Abstract available


  145. GLOGER S, Ubrig B, Boy A, Leyh-Bannurah SR, et al
    Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy.
    J Urol. 2022;208:333-340.
    PubMed     Abstract available


  146. GOODE PS, Johnson TM 2nd, Newman DK, Vaughan CP, et al
    Perioperative Mobile Telehealth Program for Post-Prostatectomy Incontinence: A Randomized Clinical Trial.
    J Urol. 2022;208:379-387.
    PubMed     Abstract available


  147. ABOU ZEINAB M, Beksac AT, Corse T, Talamini S, et al
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management.
    J Urol. 2022;208:369-378.
    PubMed     Abstract available


    July 2022
  148. BRANT A, Lewicki P, Wu X, Sze C, et al
    Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer.
    J Urol. 2022 Jul 28:101097JU0000000000002857. doi: 10.1097/JU.0000000000002857.
    PubMed     Abstract available


  149. EASTHAM JA, Boorjian SA, Kirkby E
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
    J Urol. 2022 Jul 5:101097JU0000000000002854. doi: 10.1097/JU.0000000000002854.
    PubMed    


  150. WESTHOFEN T, Buchner A, Kasivisvanathan V, Lennartz S, et al
    The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
    J Urol. 2022 Jul 5:101097JU0000000000002826. doi: 10.1097/JU.0000000000002826.
    PubMed     Abstract available


  151. FAN S, Zhang Z, Wang J, Xiong S, et al
    Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
    J Urol. 2022;208:119-127.
    PubMed     Abstract available


  152. TOPS SCM, Grootenhuis JGA, Derksen AM, Giardina F, et al
    The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications.
    J Urol. 2022;208:109-118.
    PubMed     Abstract available


    June 2022
  153. STINESEN KOLLBERG K, Holmberg E, Josefsson A, Hugosson J, et al
    Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial.
    J Urol. 2022 Jun 30:101097JU0000000000002835. doi: 10.1097/JU.0000000000002835.
    PubMed     Abstract available


  154. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jun 27:101097JU0000000000002796. doi: 10.1097/JU.0000000000002796.
    PubMed    


  155. XUE X, Yang X, Ji Z, Xie Y, et al
    Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men. Letter.
    J Urol. 2022 Jun 21:101097JU0000000000002830. doi: 10.1097/JU.0000000000002830.
    PubMed    


  156. ABOU ZEINAB M, Kaouk J
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply.
    J Urol. 2022 Jun 3:101097JU0000000000002785. doi: 10.1097/JU.0000000000002785.
    PubMed    


  157. TIAN Y, Zhang H, Luo G
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Letter.
    J Urol. 2022 Jun 3:101097JU0000000000002784. doi: 10.1097/JU.0000000000002784.
    PubMed    


  158. TURCHAN WT, Cutright D, Wu T, Leng JX, et al
    Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
    J Urol. 2022;207:1236-1245.
    PubMed     Abstract available


    May 2022
  159. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 May 20:101097JU0000000000002745. doi: 10.1097/JU.0000000000002745.
    PubMed    


  160. STEPHENSON AJ, Vourganti S
    Pro: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
    J Urol. 2022 May 12:101097JU0000000000002776. doi: 10.1097/JU.0000000000002776.
    PubMed    


  161. SIDDIQUI MM
    Con: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
    J Urol. 2022 May 12:101097JU0000000000002777. doi: 10.1097/JU.0000000000002777.
    PubMed    


  162. COLE AP, Chen X, Langbein BJ, Giganti F, et al
    Geographic Variability, Time Trends and Association of Preoperative MRI with Surgical Outcomes for Elderly US Men with Prostate Cancer: A SEER-Medicare Analysis.
    J Urol. 2022 May 10:101097JU0000000000002736. doi: 10.1097/JU.0000000000002736.
    PubMed     Abstract available


  163. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery and Follow-up.
    J Urol. 2022 May 10:101097JU0000000000002758. doi: 10.1097/JU.0000000000002758.
    PubMed     Abstract available


  164. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management.
    J Urol. 2022 May 10:101097JU0000000000002757. doi: 10.1097/JU.0000000000002757.
    PubMed     Abstract available


  165. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.
    J Urol. 2022 May 10:101097JU0000000000002759. doi: 10.1097/JU.0000000000002759.
    PubMed     Abstract available


  166. ZHANG Y, Song M, Mucci LA, Giovannucci EL, et al
    Regular, Long-Duration Multivitamin Use and Risk of Overall and Aggressive Prostate Cancer in the Health Professionals Follow-Up Study.
    J Urol. 2022 May 6:101097JU0000000000002735. doi: 10.1097/JU.0000000000002735.
    PubMed     Abstract available


  167. RADHAKRISHNAN A, Wallner LP, Skolarus TA, George AK, et al
    Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
    J Urol. 2022 May 6:101097JU0000000000002734. doi: 10.1097/JU.0000000000002734.
    PubMed     Abstract available



  168. Findings in 1,123 Men with Preoperative (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Im
    J Urol. 2022;207:1166.
    PubMed    


  169. GONDOPUTRO W, Thompson J, Evans M, Bolton D, et al
    How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires.
    J Urol. 2022;207:1048-1056.
    PubMed     Abstract available


    April 2022
  170. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Apr 25:101097JU0000000000002705. doi: 10.1097/JU.0000000000002705.
    PubMed    


  171. FRANLUND M, Mansson M, Godtman RA, Aus G, et al
    Results from 22 years of Follow-Up in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial.
    J Urol. 2022 Apr 15:101097JU0000000000002696. doi: 10.1097/JU.0000000000002696.
    PubMed     Abstract available


  172. LEWICKI P, Brant A, Shoag JE
    Re: A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
    J Urol. 2022 Apr 8:101097JU0000000000002700. doi: 10.1097/JU.0000000000002700.
    PubMed    


  173. NYAME YA, Schraidt JA, Chakoian M, Nissenberg MG, et al
    A Patient-Centered Approach to Research Prioritization in Prostate Cancer.
    J Urol. 2022 Apr 8:101097JU0000000000002694. doi: 10.1097/JU.0000000000002694.
    PubMed     Abstract available


  174. JIBARA GA, Perera M, Vertosick EA, Sjoberg DD, et al
    Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.
    J Urol. 2022 Apr 4:101097JU0000000000002668. doi: 10.1097/JU.0000000000002668.
    PubMed     Abstract available


  175. DASKIVICH TJ, Gale R, Luu M, Naser-Tavakolian A, et al
    Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.
    J Urol. 2022 Apr 4:101097JU0000000000002675. doi: 10.1097/JU.0000000000002675.
    PubMed     Abstract available


  176. PERERA M, Assel MJ, Benfante NE, Vickers AJ, et al
    Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
    J Urol. 2022 Apr 1:101097JU0000000000002685. doi: 10.1097/JU.0000000000002685.
    PubMed     Abstract available


    March 2022
  177. MONTORSI F, Mazzone E, Gandaglia G, Stabile A, et al
    Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
    J Urol. 2022 Mar 29:101097JU0000000000002680. doi: 10.1097/JU.0000000000002680.
    PubMed    


  178. CHIERIGO F, Borghesi M, Mantica G, Terrone C, et al
    Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Reply.
    J Urol. 2022 Mar 29:101097JU0000000000002681. doi: 10.1097/JU.0000000000002681.
    PubMed    


  179. DURSUN F, Wang CP, MacCarthy D, Mansour AM, et al
    Absolute PSA after 6 Months of Androgen Deprivation Therapy is a Predictor of Overall and Cancer Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.
    J Urol. 2022 Mar 28:101097JU0000000000002676. doi: 10.1097/JU.0000000000002676.
    PubMed     Abstract available


  180. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Mar 17:101097JU0000000000002511. doi: 10.1097/JU.0000000000002511.
    PubMed    


  181. BRIGHT JR, Lis RT, Ku AT, Terrigino NT, et al
    PROSTATE-SPECIFIC Membrane Antigen Is a Biomarker for Residual Disease Following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
    J Urol. 2022 Mar 1:101097JU0000000000002492. doi: 10.1097/JU.0000000000002492.
    PubMed     Abstract available


  182. KAN KM, Tin AL, Stearns GL, Eastham JA, et al
    De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors.
    J Urol. 2022;207:601-608.
    PubMed     Abstract available


  183. BAHOUTH Z, Laniado M, Fowler R, Charlesworth PJS, et al
    Positive Surgical Margins Rate of Retzius-Sparing Robot-Assisted Radical Prostatectomy in a Contemporary, Unselected Cohort.
    J Urol. 2022;207:609-616.
    PubMed     Abstract available


    February 2022
  184. KAWA SM, Stroomberg HV, Larsen SB, Helgstrand JT, et al
    A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
    J Urol. 2022 Feb 25:101097JU0000000000002491. doi: 10.1097/JU.0000000000002491.
    PubMed     Abstract available


  185. MAGNANI CJ, Hernandez-Boussard T, Baker LC, Goldhaber-Fiebert JD, et al
    Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
    J Urol. 2022 Feb 25:101097JU0000000000002490. doi: 10.1097/JU.0000000000002490.
    PubMed     Abstract available


  186. KANG DW, Fairey AS, Boule NG, Field CJ, et al
    A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance.
    J Urol. 2022 Feb 17:101097JU0000000000002334. doi: 10.1097/JU.0000000000002334.
    PubMed     Abstract available


  187. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Feb 16:101097JU0000000000002477. doi: 10.1097/JU.0000000000002477.
    PubMed    


  188. LOEB S, Borno HT, Gomez S, Ravenell J, et al
    Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.
    J Urol. 2022 Feb 4:101097JU0000000000002257. doi: 10.1097/JU.0000000000002257.
    PubMed     Abstract available


  189. KACHANOV M, Leyh-Bannurah SR, Roberts MJ, Sauer M, et al
    Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
    J Urol. 2022;207:333-340.
    PubMed     Abstract available


  190. OTLES E, Denton BT, Qu B, Murali A, et al
    Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National Cohorts.
    J Urol. 2022;207:358-366.
    PubMed     Abstract available


  191. CLEMENTS MB, Tin AL, Estes CL, Jibara G, et al
    Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications.
    J Urol. 2022;207:367-374.
    PubMed     Abstract available


    January 2022
  192. ANDRUSKA N, Fischer-Valuck BW, Waters M, Diaz EJ, et al
    Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-only versus Whole Pelvic Radiation Therapy.
    J Urol. 2022 Jan 27:101097JU0000000000002455. doi: 10.1097/JU.0000000000002455.
    PubMed     Abstract available


  193. KUPPERMANN D, Calais J, Marks LS
    Imaging Prostate Cancer: Clinical Utility of Prostate-specific Membrane Antigen (PSMA).
    J Urol. 2022 Jan 27:101097JU0000000000002457. doi: 10.1097/JU.0000000000002457.
    PubMed     Abstract available


  194. SCHIFF H
    Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. Letter.
    J Urol. 2022 Jan 26:101097JU0000000000002456. doi: 10.1097/JU.0000000000002456.
    PubMed    


  195. ROSENBERG JE, Jarosek S, Spilseth B, Huang YH, et al
    Diagnosing Prostate Cancer: The Role of Intravesicular Prostatic Gland Protrusion on Accuracy of Prostate Biopsies.
    J Urol. 2022 Jan 26:101097JU0000000000002448. doi: 10.1097/JU.0000000000002448.
    PubMed     Abstract available


  196. EGGENER S, Siemens DR
    Prostate Cancer, Decisional Regret and Exercise.
    J Urol. 2022 Jan 26:101097JU0000000000002453. doi: 10.1097/JU.0000000000002453.
    PubMed    


  197. WANG M, Semerjian A, Lane BR, George AK, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
    J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.
    PubMed    


  198. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
    J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
    PubMed     Abstract available


  199. SHAHAIT M, Cheaib JG, Davicioni E, Liu Y, et al
    Does Perioperative Testosterone Predict Post-prostatectomy Genomic Risk Score?
    J Urol. 2022 Jan 20:101097JU0000000000002440. doi: 10.1097/JU.0000000000002440.
    PubMed     Abstract available


  200. PAN A, Reingold RE, Zhao JL, Moy A, et al
    Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
    J Urol. 2022 Jan 12:101097JU0000000000002425. doi: 10.1097/JU.0000000000002425.
    PubMed     Abstract available


  201. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
    PubMed    


  202. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
    Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
    J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
    PubMed     Abstract available


  203. NAYAK JG
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
    J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
    PubMed    


  204. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
    J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
    PubMed    


  205. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
    The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
    PubMed     Abstract available


  206. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
    Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
    J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
    PubMed     Abstract available


  207. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
    Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
    J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
    PubMed     Abstract available


  208. LEE A, Chen K, Tay KJ
    Can We Avoid a Systematic Biopsy in Men with PI-RADS((R)) 5? Letter.
    J Urol. 2022;207:240-241.
    PubMed    


  209. TAFURI A, Iwata A, Shakir A, Iwata T, et al
    Can We Avoid a Systematic Biopsy in Men with PI-RADS(R) 5? Reply.
    J Urol. 2022;207:241-242.
    PubMed    


  210. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
    Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
    J Urol. 2022;207:118-126.
    PubMed     Abstract available


  211. CHANG P, Wagner AA, Regan MM, Smith JA, et al
    Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
    J Urol. 2022;207:127-136.
    PubMed     Abstract available


  212. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
    Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
    J Urol. 2022;207:95-107.
    PubMed     Abstract available


  213. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    J Urol. 2022;207:108-117.
    PubMed     Abstract available


    December 2021
  214. WASHINGTON SL 3RD, Gore JL, Nyame YA
    Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.
    J Urol. 2021 Dec 30:101097JU0000000000002417. doi: 10.1097/JU.0000000000002417.
    PubMed    


  215. ALKHATIB K, Labban M, Briggs L, Nguyen DD, et al
    Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate-specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
    J Urol. 2021 Dec 30:101097JU0000000000002379. doi: 10.1097/JU.0000000000002379.
    PubMed     Abstract available


  216. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Dec 17:101097JU0000000000002377. doi: 10.1097/JU.0000000000002377.
    PubMed    


  217. KAN WC, Hsieh KL, Chen YC, Ho CH, et al
    Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients With Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002340. doi: 10.1097/JU.0000000000002340.
    PubMed     Abstract available


  218. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002335. doi: 10.1097/JU.0000000000002335.
    PubMed     Abstract available


  219. KINNAIRD A, Yerram NK, O'Connor L, Brisbane W, et al
    MRI-guided Biopsy in Active Surveillance of Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002343. doi: 10.1097/JU.0000000000002343.
    PubMed     Abstract available


  220. WAISMAN MALARET AJ, Chang P, Zhu K, Zheng Y, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
    J Urol. 2021 Dec 2:101097JU0000000000002354. doi: 10.1097/JU.0000000000002354.
    PubMed     Abstract available


  221. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
    Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
    J Urol. 2021;206:1403-1410.
    PubMed     Abstract available


    November 2021
  222. CHEN K, Murphy D, Lawrentschuk N
    Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
    J Urol. 2021 Nov 17:101097JU0000000000002348. doi: 10.1097/JU.0000000000002348.
    PubMed    


  223. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Nov 17:101097JU0000000000002326. doi: 10.1097/JU.0000000000002326.
    PubMed    


  224. COOPERBERG MR, Lin DW, Morgan TM, Chapin BF, et al
    Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
    J Urol. 2021 Nov 15:101097JU0000000000002341. doi: 10.1097/JU.0000000000002341.
    PubMed    


  225. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
    J Urol. 2021;206:1192-1203.
    PubMed     Abstract available


  226. KOWALCZYK KJ, Madi RH, Eden CG, Sooriakumaran P, et al
    Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.
    J Urol. 2021;206:1184-1191.
    PubMed     Abstract available


    October 2021
  227. LEE MC, Erickson TR, Stock S, Howard LE, et al
    Association Between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes Among Patients with Intermediate- and High-Risk Localized Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002304. doi: 10.1097/JU.0000000000002304.
    PubMed     Abstract available


  228. LOZANO-LORCA M, Olmedo-Requena R, Rodriguez-Barranco M, Redondo-Sanchez D, et al
    Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
    J Urol. 2021 Oct 25:101097JU0000000000002294. doi: 10.1097/JU.0000000000002294.
    PubMed     Abstract available


  229. DASKIVICH TJ, Luu M, Freedland SJ, Sandler H, et al
    Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002256. doi: 10.1097/JU.0000000000002256.
    PubMed     Abstract available


  230. YU W, Guo J
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
    J Urol. 2021 Oct 25:101097JU0000000000002302. doi: 10.1097/JU.0000000000002302.
    PubMed    


  231. RAVEENTHIRAN S, Yaxley WJ, Franklin T, Coughlin G, et al
    Findings in 1123 Men with Pre-operative (68)Ga-PSMA PET/CT and mpMRI Compared to Totally Embedded Radical Prostatectomy Histopathology. Implications for the Diagnosis and Management of Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002293. doi: 10.1097/JU.0000000000002293.
    PubMed     Abstract available



  232. Urological Oncology: Prostate Cancer.
    J Urol. 2021 Oct 18:101097JU0000000000002285. doi: 10.1097/JU.0000000000002285.
    PubMed    


  233. KAPLAN-MARANS E
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.J Urol; 206: 613.
    J Urol. 2021 Oct 11:101097JU0000000000002288. doi: 10.1097/JU.0000000000002288.
    PubMed    


  234. ZHANG KW, Guha A
    Response to "Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS): Letter."
    J Urol. 2021 Oct 11:101097JU0000000000002289. doi: 10.1097/JU.0000000000002289.
    PubMed    


  235. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
    Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
    J Urol. 2021;206:894-902.
    PubMed     Abstract available


  236. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
    A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
    J Urol. 2021;206:942-951.
    PubMed     Abstract available


    September 2021
  237. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
    PubMed     Abstract available


  238. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
    Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
    J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
    PubMed     Abstract available


  239. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
    An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
    J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
    PubMed     Abstract available


  240. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
    (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
    J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
    PubMed     Abstract available


  241. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
    Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
    PubMed     Abstract available


  242. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
    J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
    PubMed    


  243. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Sep 9:101097JU0000000000002226. doi: 10.1097/JU.0000000000002226.
    PubMed    


  244. GREENBERG SA, Washington SL 3rd, Lonergan PE, Cowan JE, et al
    Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    J Urol. 2021;206:706-714.
    PubMed     Abstract available


  245. EHDAIE B, Jibara G, Sjoberg DD, Laudone V, et al
    The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.
    J Urol. 2021;206:662-668.
    PubMed     Abstract available


  246. HINES L, Zhu D, DeMasi M, Babar M, et al
    A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS(R) Score and Ethnicity in a Diverse, Multiethnic Population.
    J Urol. 2021;206:586-594.
    PubMed     Abstract available


  247. SOERENSEN SJC, Fan RE, Seetharaman A, Chen L, et al
    Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy.
    J Urol. 2021;206:604-612.
    PubMed     Abstract available


    August 2021
  248. KIM M, Wu S, Lin SX, Crotty RK, et al
    Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
    J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
    PubMed     Abstract available


  249. TIMILSHINA N, Komisarenko M, Martin LJ, Cheung DC, et al
    Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study.
    J Urol. 2021 Aug 20:101097JU0000000000001903. doi: 10.1097/JU.0000000000001903.
    PubMed     Abstract available


  250. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Aug 18:101097JU0000000000002174. doi: 10.1097/JU.0000000000002174.
    PubMed    


  251. COOLEY LF, Emeka AA, Meyers TJ, Cooper PR, et al
    Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
    J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937.
    PubMed     Abstract available


  252. KHEDIME S, Gelet A, Rouviere O, Lafon C, et al
    Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
    J Urol. 2021;206:325-337.
    PubMed     Abstract available


  253. TAFURI A, Iwata A, Shakir A, Iwata T, et al
    Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
    J Urol. 2021;206:289-297.
    PubMed     Abstract available


  254. KUMAR RM, Fergusson DA, Lavallee LT, Cagiannos I, et al
    Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.
    J Urol. 2021;206:346-353.
    PubMed     Abstract available


    July 2021
  255. RYAN CJ, Ke X, Lafeuille MH, Romdhani H, et al
    Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
    J Urol. 2021 Jul 23:101097JU0000000000002121. doi: 10.1097/JU.0000000000002121.
    PubMed     Abstract available


  256. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jul 20:101097JU0000000000002132. doi: 10.1097/JU.0000000000002132.
    PubMed    


  257. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
    Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
    J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
    PubMed     Abstract available


  258. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
    Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
    J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
    PubMed     Abstract available


  259. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
    Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
    J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
    PubMed     Abstract available


    June 2021
  260. TREMBLAY S, Summers-Trasiewicz L, Pouliot F, Crook JM, et al
    Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
    J Urol. 2021 Jun 29:101097JU0000000000001946. doi: 10.1097/JU.0000000000001946.
    PubMed     Abstract available


  261. OAKE JD, Harasemiw O, Tangri N, Ferguson TW, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis.
    J Urol. 2021 Jun 28:101097JU0000000000001942. doi: 10.1097/JU.0000000000001942.
    PubMed     Abstract available


  262. WILLIAMS C, Khondakar NR, Daneshvar MA, O'Connor LP, et al
    The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.
    J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941.
    PubMed     Abstract available


  263. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jun 21:101097JU0000000000001921. doi: 10.1097/JU.0000000000001921.
    PubMed    


  264. INABA H, Kimura T, Onuma H, Kido M, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men. Reply.
    J Urol. 2021;205:1841-1842.
    PubMed    


  265. VAN KALMTHOUT L, Braat A, de Keizer B, Lam M, et al
    Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
    J Urol. 2021;205:1839-1840.
    PubMed    


  266. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
    Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
    J Urol. 2021;205:1663-1670.
    PubMed     Abstract available


  267. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
    National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
    J Urol. 2021;205:1641-1647.
    PubMed     Abstract available


  268. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
    Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
    J Urol. 2021;205:1681-1688.
    PubMed     Abstract available


    May 2021
  269. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
    Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
    J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
    PubMed     Abstract available


  270. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
    Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
    J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
    PubMed     Abstract available


  271. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
    Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
    J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
    PubMed     Abstract available


  272. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
    Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
    J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
    PubMed     Abstract available


  273. MACDONALD S, Matos A, Wambier C
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
    J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.
    PubMed    


  274. KLEIN EA
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
    J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.
    PubMed    


  275. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.
    PubMed    


  276. SHAH N, Ioffe V
    Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
    J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
    PubMed    


  277. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.
    J Urol. 2021;205:1528-1529.
    PubMed    


  278. STAVRINIDES V, Giganti F, Allen C, Kirkham A, et al
    Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.J Urol 2021; 205: 748.
    J Urol. 2021;205:1526-1528.
    PubMed    


  279. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
    Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
    J Urol. 2021;205:1344-1351.
    PubMed     Abstract available


  280. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed     Abstract available


    April 2021
  281. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
    Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
    PubMed     Abstract available


  282. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
    Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
    J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
    PubMed     Abstract available


  283. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
    Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
    J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
    PubMed     Abstract available


  284. FAN L, Fei X, Zhu Y, Chi C, et al
    Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
    PubMed     Abstract available


  285. RAJWA P, Mori K, Huebner NA, Martin DT, et al
    The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
    PubMed     Abstract available


  286. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
    Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
    J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
    PubMed     Abstract available


  287. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
    PubMed    


  288. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
    PubMed     Abstract available


  289. LIN PH, Howard L, Freedland SJ
    Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
    J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
    PubMed    


  290. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
    Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
    PubMed     Abstract available


  291. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
    Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
    J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
    PubMed     Abstract available


    March 2021
  292. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
    Performance of Prostate Health Index in Biopsy Naive Black Men.
    J Urol. 2021;205:718-724.
    PubMed     Abstract available


  293. UMARI P, Eden C, Cahill D, Rizzo M, et al
    Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
    J Urol. 2021;205:780-790.
    PubMed     Abstract available


  294. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
    Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    J Urol. 2021;205:732-739.
    PubMed     Abstract available


  295. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    J Urol. 2021;205:748-754.
    PubMed     Abstract available


  296. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
    Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    J Urol. 2021;205:740-747.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.